LYRA

Lyra Therapeutics, Inc. LYRA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.6M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$7.0K

Quarter to Dec 31

Net income

$-6.95M

Quarter to Dec 31

Free cash flow

$-6.16M

Quarter to Dec 31

Top Institutional Holders

as of Q1 2026
$51.1K total
SABBY MANAGEMENT, LLC
$51.1K-40.6%
See all 1 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q4 2025
EDGAR

Net Income

Q4 2025
EDGAR

Free Cash Flow

Q4 2025
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LYRA

Earnings Per Share

13fpro.ai/company/LYRA

Loading ratio trend…

LYRA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Lyra Therapeutics, Inc.'s annual filings on SEC EDGAR.

Lyra Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$398.0K$-28.9M—
FY 2024$1.5M$-93.4M—
FY 2023$1.6M$-62.7M—
FY 2022$1.4M$-55.3M—
FY 2021$285.0K$-43.5M—
Source: LYRA filings on SEC EDGAR →

LYRA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Lyra Therapeutics, Inc. (LYRA): stock profile, AI score and financials

Lyra Therapeutics, Inc. (LYRA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. LYRA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.6m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q4 2025), Lyra Therapeutics, Inc. reports quarterly revenue of $7.0K, net income of $-7.0M, free cash flow of $-6.2M. LYRA trades on the Nasdaq exchange and files with the SEC under CIK 1327273. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LYRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lyra Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1327273 →